“While it was so widely expected the announcement was merely a formality, just after 5pm on Friday the FDA Advisory Panel voted unanimously (22-0) to endorse the (one-shot, no mRNA) J&J vaccine, saying the benefits outweigh the risks, and recommended the agency grant emergency authorization, moving the nation's third vaccine one step closer to getting into Americans' arms.”
The is the advisory committee of the FDA. FDA approval could come as early as tomorrow.Read more
GOP Senators Demand FDA Explain Hydroxychloroquine Stance Amid Positive Studies And Physician Advocates
“The debate over hydroxychloroquine has faded from the forefront as big tech has worked to suppress information and silence the voices of doctors and researchers promoting it. However, it appears the controversy over the drug has encouraged some senators to take a closer look, and it seems they are asking the FDA the right questions.”Read more
A month-old request from a Michigan hospital for emergency use authorization to treat COVID-19 patients with hydroxychloroquine has been denied by the U.S. Food and Drug Administration.
Thanks, Western Journal.Read more
Now ask yourself who benefits from this?Read more
"I wanted to trust Dr. Anthony Fauci. I really did. Early in the pandemic, I took the advice of Dr. Drew Pinsky and listened to what he said. Maybe I listened too closely. Lockdowns leave a person a lot of free time, and a Google machine and keyboard are an excellent way to pass the time."Read more
“A Tucson-based national organization of doctors has sued the federal Department of Health and Human Services for putting roadblocks in the path of physicians who want to prescribe hydroxychloroquine to prevent COVID-19.”Read more
“CEI Senior Fellow Michelle Minton found that a vast majority of congressional funding allotted to the Centers for Disease Control (CDC) and Food and Drug Administration (FDA) went towards reinforcing public behavior while only a fraction of the agency budgets were targeted towards fighting emerging pathogens that have given rise to the public health pandemic today.”Read more
Stocks Soar On Fauci-Touted Remdesivir Study Despite Marginal Survival Benefit, Snubs Lancet Findings
"Update (13:15ET): The NIAD has released a statement on the Gilead remdesivir study. The statement repeated some of the numbers Dr. Fauci shared at the press conference - that patients who took remdesivir saw 31% faster time to recovery than the placebo group, while mortality rates "improved" to 8% from 11.6% an improvement of 3.6 percentage points, which Dr. Fauci acknowledged wasn't "statistically significant.""
See the first comment for an unencouraging update.Read more